QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
NASDAQ:ERNA

Eterna Therapeutics (ERNA) Stock Forecast, Price & News

$2.13
+0.04 (+1.91%)
(As of 09/27/2023 ET)
Compare
Today's Range
$2.05
$2.23
50-Day Range
$2.03
$2.89
52-Week Range
$1.90
$7.15
Volume
4,167 shs
Average Volume
17,733 shs
Market Capitalization
$11.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ERNA stock logo

About Eterna Therapeutics (NASDAQ:ERNA) Stock

Eterna Therapeutics Inc. operates as a preclinical-stage, biopharmaceutical company. The company offers Synthetic mRNA, ToRNAdo mRNA Delivery, mRNA Gene Editing, and mRNA Cell Reprogramming. It also develops therapies and medicines using gene-editing proteins and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. The company was formerly known as Brooklyn ImmunoTherapeutics, Inc. and changed its name to Eterna Therapeutics Inc. in October 2022. Eterna Therapeutics Inc. is based in Cambridge, Massachusetts.

ERNA Price History

ERNA Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
ERNA Eterna Therapeutics Inc.
See More Headlines
Receive ERNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eterna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ERNA Company Calendar

Last Earnings
8/11/2023
Today
9/27/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ERNA
Employees
9
Year Founded
N/A

Profitability

Net Income
$-24,580,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5.80 million
Book Value
$4.12 per share

Miscellaneous

Free Float
3,493,000
Market Cap
$11.47 million
Optionable
Not Optionable
Beta
4.27
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Matthew Angel Ph.D. (Age 42)
    CEO & Pres
    Comp: $240.8k
  • Ms. Sandra M. Gurrola (Age 56)
    Principal Financial & Accounting Officer and VP of Fin.
  • Ms. Megan Yung
    Chief Strategy Officer













ERNA Stock - Frequently Asked Questions

How have ERNA shares performed in 2023?

Eterna Therapeutics' stock was trading at $3.22 at the beginning of the year. Since then, ERNA stock has decreased by 34.2% and is now trading at $2.12.
View the best growth stocks for 2023 here
.

Are investors shorting Eterna Therapeutics?

Eterna Therapeutics saw a increase in short interest in September. As of September 15th, there was short interest totaling 130,500 shares, an increase of 21.3% from the August 31st total of 107,600 shares. Based on an average trading volume of 12,800 shares, the days-to-cover ratio is currently 10.2 days. Currently, 4.4% of the company's shares are sold short.
View Eterna Therapeutics' Short Interest
.

When is Eterna Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ERNA earnings forecast
.

How were Eterna Therapeutics' earnings last quarter?

Eterna Therapeutics Inc. (NASDAQ:ERNA) announced its earnings results on Friday, August, 11th. The company reported ($0.85) earnings per share for the quarter.

What is Eterna Therapeutics' stock symbol?

Eterna Therapeutics trades on the NASDAQ under the ticker symbol "ERNA."

Who are Eterna Therapeutics' major shareholders?

Eterna Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Sippican Capital Advisors (0.41%), BlackRock Inc. (0.34%) and Goldman Sachs Group Inc. (0.21%). Insiders that own company stock include John D Halpern and Nicholas Jason Singer.
View institutional ownership trends
.

How do I buy shares of Eterna Therapeutics?

Shares of ERNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eterna Therapeutics' stock price today?

One share of ERNA stock can currently be purchased for approximately $2.12.

How much money does Eterna Therapeutics make?

Eterna Therapeutics (NASDAQ:ERNA) has a market capitalization of $11.47 million and generates $5.80 million in revenue each year. The company earns $-24,580,000.00 in net income (profit) each year or ($5.64) on an earnings per share basis.

How can I contact Eterna Therapeutics?

Eterna Therapeutics' mailing address is 10355 Science Center Drive SUITE 150, San Diego CA, 92121. The official website for the company is www.brooklynitx.com. The company can be reached via phone at (212) 582-1199, via email at investors@brooklynitx.com, or via fax at 760-438-3505.

This page (NASDAQ:ERNA) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -